CHCHD7

Across TCGA pan-cancer cohorts, CHCHD7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHCHD7 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHCHD7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHCHD7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where CHCHD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.663	0.356	.001	35	view →
LSCC	DFS	Tertile	All	1.000	0.401	.008	12	view →
UCEC	DFS	Tertile	III,IV	1.000	0.389	.020	8	view →
HNSC	OS	Median	All	0.959	1.000	.023	8	view →
CCRCC	DFS	Quartile	All	0.638	0.901	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHCHD7–PDAC (DFS)

Open the PDAC breakdown →